Kymriah pioneer Carl June is back, with first US human evidence for CRISPR use in cancer – Endpoints News

Posted: February 9, 2020 at 1:50 pm

Biogen $BIIB just won one of the biggest fights its ever faced.

The big biotech beat Mylans challenge on the patents that guard their cash cow, Tecfidera, the multiple sclerosis drug that drove the companys comeback under George Scangos and sustains his successor Michel Vounatsos as they search for new drugs.

In the inter partes review ruling, the Patent Trial and Appeal Board or PTAB determined:Having considered all the evidence, petitioner has not demonstrated by a preponderance of the evidence the unpatentability of claims 1-20 of the 514 patent.The news, a closely watched catalyst that had analysts on high alert, immediately triggered a huge 29% spike in their share price. Tecfidera earned $3.3 billion in 2019, almost half its revenue for the year.

Unlock this story instantly and join 71,700+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Here is the original post:
Kymriah pioneer Carl June is back, with first US human evidence for CRISPR use in cancer - Endpoints News

Related Post

Comments are closed.

Archives